Chemotherapy based on cytotoxic drugs has always been a primary method for treating malignant tumors. However, due to the lack of targeted killing of tumor cells, there are significant toxic reactions, and as the number of chemotherapy cycles increases, tumor resistance also enhances. The challenge of how to target tumor cells to deliver cytotoxic drugs … Read more
[Image] Antibody-drug conjugates (ADCs) are a class of emerging anti-cancer drugs that can directly deliver highly cytotoxic molecules to cancer cells. To date, 12 ADC drugs have received market approval. ADCs are formed by the covalent linkage of monoclonal antibodies and cytotoxins through linkers. Research indicates that linkers play a crucial role in ADC drugs, … Read more
Antibody-Drug Conjugates (ADCs) are precision anti-cancer drugs that combine the targeting ability of antibodies with potent cytotoxic agents, achieving precise strikes against tumor cells through a “biological missile” design. As of July 2025, a total of 19 ADC drugs have been approved globally, widely used in the treatment of various cancers such as breast cancer … Read more
The Metabolism Process of ADC The in vivo delivery process of the payload is complicated due to the complex structure of ADCs and their metabolic degradation in the body. After ADC administration, the Drug-to-Antibody Ratio (DAR), bound or free antibodies, albumin conjugates, free payloads, and payload metabolites are all in a highly dynamic state over … Read more
The development of next-generation ADC drugs has gradually shifted towards the development of new toxins and linkers as foundational technologies. Multi-antibody or multi-toxin approaches have become a new trend. Following Araris and Puzhong’s advancements in tri-toxin and hexatozin,Aarvik has now introduced quadruple antibody-drug conjugates (ADCs). Aarvik may not have a prominent reputation in the ADC … Read more
Key Components and Mechanisms of ADC Stability The instability of linkers in the bloodstream (also known as premature payload release) is a major factor limiting the therapeutic index of ADCs. Stabilization technologies are strategies to improve the therapeutic window. If the drug cannot be linked to the ADC, it cannot be delivered directly to tumor … Read more
–01– Introduction The announcement of the 2022 Nobel Prize in Chemistry brought the cutting-edge technology of “Click Chemistry” into the public eye. The groundbreaking work of three scientists has not only revolutionized the field of organic synthesis but also opened new pathways for cancer treatment—specifically, the development of Antibody-Drug Conjugates (ADC) is advancing towards a … Read more
Xinge Corporation (headquartered in Nagoya, Aichi Prefecture, Japan) recently announced that non-clinical data for its novel antibody-drug conjugate (ADUC) K-679 will be officially presented at the American Association for Cancer Research (AACR) Annual Meeting 2025, scheduled to take place from April 25 to 30, 2025, in Chicago, Illinois, USA. K-679 K-679 is an antibody-drug conjugate … Read more
Introduction As one of the most active innovative drug development areas at present, Antibody-Drug Conjugates (ADCs) are rising at an astonishing pace. The global industry interest continues to heat up, with ADC innovative drugs being approved one after another. As of March 2025, a total of 17 ADC products have been approved for market release … Read more
Follow Xiaobai Learning Medicine As of now, 17 ADC drugs have been approved worldwide, of which 5 ADCs are coupled with lysine. Table 1 Summary of ADC Drugs Coupled with Lysine Approved Product Name Company Target DAR Toxin Linker Antibody Type Payload Type Mylotarg Pfizer CD33 2~3 Calicheamicin Hydrazone Link (Acid-labile) IG4 DNA Damaging Agent … Read more